C6orf174 Inhibitors
Chemical inhibitors of the protein regulated by the gene C6orf174 can modulate its activity through various intracellular signaling pathways. Staurosporine, a potent and non-selective protein kinase inhibitor, can disrupt numerous kinase-dependent processes, potentially including those that activate the protein. Similarly, Bisindolylmaleimide I, by targeting protein kinase C (PKC), can inhibit the activation of proteins that function within the same pathway as the protein in question. LY294002, by specifically inhibiting phosphoinositide 3-kinases (PI3K), can suppress the PI3K/AKT pathway, leading to the downregulation of activities downstream that may be crucial for the protein's function. Another compound, PD98059, focuses on MEK1/2 enzymes within the MAPK/ERK pathway, which, when inhibited, can lead to decreased activation of the protein. U0126, which also targets MEK, serves a similar function in possibly preventing the protein's activity by inhibiting the upstream activation of ERK1/2.
Further, SP600125, which inhibits the c-Jun N-terminal kinase (JNK), can prevent the transcriptional activation of factors that may be necessary for the protein's functionality. SB203580's inhibition of p38 MAPK, a protein kinase responding to stress signals, can result in the downregulation of the protein's activity if it is part of the stress response pathway. Wortmannin, another PI3K inhibitor, can impede the PI3K/AKT signaling cascade, thereby possibly affecting the protein's activity indirectly. Rapamycin, targeting the mTOR pathway, can suppress downstream processes that may involve the protein. Dasatinib, a Src family kinase inhibitor, can disrupt kinase-dependent signaling pathways, possibly leading to the downregulation of the protein. PP2, another selective Src kinase inhibitor, can lead to similar outcomes by preventing the kinase activity that may be necessary for the protein's functionality. Lastly, Go6983, by inhibiting PKC isoforms, can downregulate signaling pathways that may include the protein, leading to its decreased activity. Each chemical inhibitor, by targeting specific kinases or pathways, can affect the protein's activity by altering the phosphorylation state or the availability of essential cofactors required for its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits a broad range of protein kinases. Considering C6orf174's function is likely linked to a specific kinase-dependent signaling pathway, staurosporine can inhibit the kinase that activates C6orf174, leading to its functional inhibition. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I targets protein kinase C (PKC), which is involved in numerous signaling pathways. Inhibition of PKC can lead to reduced phosphorylation and activation of proteins downstream or within the same pathway as C6orf174, resulting in the functional inhibition of C6orf174. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). It can inhibit the PI3K/AKT pathway, which could be regulating C6orf174's function indirectly. By inhibiting this pathway, LY294002 can lead to the functional inhibition of C6orf174 due to a reduction in the pathway's downstream signaling that may be necessary for C6orf174's activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 specifically inhibits MEK1/2, key enzymes in the MAPK/ERK pathway. Since C6orf174 is associated with cellular signaling, inhibiting MEK can lead to decreased ERK activity and thus inhibit the signaling pathway that may be responsible for C6orf174's activation, resulting in the functional inhibition of C6orf174. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of ERK1/2. By blocking this pathway, U0126 can inhibit the signaling cascade that may include C6orf174, leading to its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), which is part of the stress-activated protein kinase pathway. Inhibition of JNK can prevent the activation of transcription factors and other proteins that might be necessary for C6orf174's function, leading to its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, which is involved in response to stress and cytokines. If C6orf174 is functionally related to proteins in the p38 MAPK pathway, inhibition of this pathway by SB203580 would result in functional inhibition of C6orf174. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K and can inhibit the PI3K/AKT signaling pathway. By inhibiting PI3K, wortmannin can prevent the downstream activation of targets within the pathway that C6orf174 may be functionally dependent on, thus inhibiting C6orf174's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits the mTOR pathway, which is involved in cell growth, proliferation, and survival. Inhibition of mTOR can suppress the activity of downstream proteins that could be involved in the same signaling networks as C6orf174, leading to its functional inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinases participate in various signaling pathways. Inhibiting Src kinases with dasatinib can lead to the disruption of signaling pathways that activate proteins including C6orf174, leading to its functional inhibition. | ||||||